Compare Medpace Holdings Inc (MEDP) vs Progressive Corp (PGR) Price & Performance

MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.

The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.

Progressive (PGR) trades at $205.9, down 0.99% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and net income rising to $11.3B. Recent Q2 2026 earnings missed expectations at $4.64 EPS, but premiums and investment income remain solid. Analyst consensus is mixed with a $234.56 price target, indicating potential upside from current levels.

The outlook for PGR is cautiously optimistic given its valuation at a P/E of 10.65 and consistent profitability. Key risks include competitive pressures in auto insurance and market volatility. Investment opportunity lies in its scale and data-driven pricing, though near-term performance may hinge on earnings execution and macroeconomic factors affecting the insurance sector.